Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
25.81
-0.20 (-0.77%)
Apr 24, 2026, 4:00 PM EDT - Market closed
Maze Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Maze Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $68.25, which forecasts a 164.43% increase in the stock price over the next year. The lowest target is $46 and the highest is $110.
Price Target: $68.25 (+164.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Maze Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $68 → $64 | Strong Buy | Maintains | $68 → $64 | +147.97% | Apr 14, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $52 → $58 | Buy | Maintains | $52 → $58 | +124.72% | Mar 31, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +78.23% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $110 | Strong Buy | Maintains | $60 → $110 | +326.19% | Mar 25, 2026 |
| Truist Securities | Truist Securities | Strong Buy Initiates $68 | Strong Buy | Initiates | $68 | +163.46% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
11.66M
Revenue Next Year
5.44M
from 11.66M
Decreased by -53.39%
EPS This Year
-2.87
from -3.05
EPS Next Year
-3.24
from -2.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 21.0M | 22.1M | ||||||
| Avg | 11.7M | 5.4M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 89.1% | ||||||
| Avg | - | -53.4% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.51 | -2.90 | ||||||
| Avg | -2.87 | -3.24 | ||||||
| Low | -3.30 | -3.64 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.